靶向CCR2的分子影像在肺纤维化中的临床试验
该研究开发了64Cu-DOTA-ECL1i放射性示踪剂,通过PET无创追踪CCR2+单核细胞和巨噬细胞。小鼠模型证实肺内示踪剂摄取增加与纤维化相关CCR2+细胞浸润相关,抗纤维化治疗可降低摄取。IPF患者肺组织CCR2+细胞聚集于纤维化周边区域并与示踪剂定位相关,健康志愿者肺摄取少而IPF患者纤维化区域信号强烈。
要点
- 64Cu-DOTA-ECL1i PET可无创追踪肺内CCR2+单核细胞和巨噬细胞。
- 小鼠模型中示踪剂肺摄取与纤维化相关CCR2+细胞浸润相关。
- IPF患者纤维化区域显示强烈示踪剂信号,健康志愿者摄取少。
核心结论
- 影像追踪IPF纤维化微环境中的CCR2+细胞可为个体化治疗和监测提供分子靶点。
研究设计与样本
- 在博来霉素或辐射诱导纤维化小鼠及IPF人类受试者中研究CCR2+细胞。
- 使用免疫定位、单细胞质谱流式、Ccr2 RNA原位杂交表征CCR2+细胞并与64Cu-DOTA-ECL1i PET定量肺摄取相关。
- 小鼠模型n=72,IL-1β阻断治疗模型n=19,吡非尼酮治疗模型n=18。
- IPF患者肺组织n=21,健康志愿者n=7,IPF受试者n=4。
主要发现
- 小鼠模型建立增加64Cu-DOTA-ECL1i PET肺摄取与纤维化相关CCR2+细胞浸润相关(n=72)。
- IL-1β阻断(n=19)或抗纤维化吡非尼酮(n=18)减少小鼠肺CCR2+巨噬细胞积聚和示踪剂摄取。
- IPF患者肺组织中CCR2+细胞集中于纤维化周边区域并与示踪剂定位相关(n=21)。
- 健康志愿者(n=7)肺摄取少,而IPF受试者(n=4)纤维化区域显示强烈信号。
临床怎么用
- 该影像方法尚处于临床研究阶段,暂不用于常规临床决策。
- 未来可能用于IPF患者CCR2靶向治疗的筛选和疗效监测。
局限性
- IPF患者影像样本量小(n=4),健康志愿者n=7。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive inflammatory lung disease without effective molecular markers of disease activity or treatment responses. Monocyte and interstitial macrophages that express the C-C motif CCR2 (chemokine receptor 2) are active in IPF and central to fibrosis.Objectives: To phenotype patients with IPF for potential targeted therapy, we developed 64Cu-DOTA-ECL1i, a radiotracer to noninvasively track CCR2+ monocytes and macrophages using positron emission tomography (PET).Methods: CCR2+ cells were investigated in mice with bleomycin- or radiation-induced fibrosis and in human subjects with IPF. The CCR2+ cell populations were localized relative to fibrotic regions in lung tissue and characterized using immunolocalization, single-cell mass cytometry, and Ccr2 RNA in situ hybridization and then correlated with parallel quantitation of lung uptake by 64Cu-DOTA-ECL1i PET.Measurements and Main Results: Mouse models established that increased 64Cu-DOTA-ECL1i PET uptake in the lung correlates with CCR2+ cell infiltration associated with fibrosis (n = 72). As therapeutic models, the inhibition of fibrosis by IL-1β blockade (n = 19) or antifibrotic pirfenidone (n = 18) reduced CCR2+ macrophage accumulation and uptake of the radiotracer in mouse lungs. In lung tissues from patients with IPF, CCR2+ cells concentrated in perifibrotic regions and correlated with radiotracer localization (n = 21). Human imaging revealed little lung uptake in healthy volunteers (n = 7), whereas subjects with IPF (n = 4) exhibited intensive signals in fibrotic zones.Conclusions: These findings support a role for imaging CCR2+ cells within the fibrogenic niche in IPF to provide a molecular target for personalized therapy and monitoring.Clinical trial registered with www.clinicaltrials.gov (NCT03492762).
引用
- Brody SL, Gunsten SP, Luehmann HP, et al. Chemokine Receptor 2-targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial. Am J Respir Crit Care Med. 2021. PMID: 32673071. doi:10.1164/rccm.202004-1132OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。